Antibodies, Monoclonal

Antibodies produced by a single clone of cells.
DrugDrug NameDrug Indication
DB00002CetuximabCetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.
DB00072TrastuzumabFor treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.
DB00073RituximabFor treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
DB00112BevacizumabAs part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.
DB05773Trastuzumab emtansineUsed in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
DB06366PertuzumabPertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
DB08935ObinutuzumabObinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
DB09037PembrolizumabPembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of:  patients with unresectable or metastatic melanoma.  patients with metastatic NSCLC whose tumors have high PD-L1 expression [(Tumor Proportion Score (TPS) ≥50%)] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.  patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.  patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
DB00056Gemtuzumab ozogamicinIndicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).
DB00110PalivizumabFor prophylaxis of respiratory diseases casued by respiratory syncytial virus.
DB00043OmalizumabFor treatment of asthma caused by allergies
DB00051AdalimumabFor treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
DB00065InfliximabTo manage the signs and symptoms, as well as to induce and maintain clinical remission in adults with moderate to severe active Crohn's disease or ulcerative colitis. Also used to manage signs and symptoms of rheumatoid arthritis (in conjunction with methotrexate), ankylosing spondylitis, psoriatic arthritis, and juvenile arthritis.
DB00075MuromonabFor treatment of organ transplant recipients, prevention of organ rejection
DB00087AlemtuzumabAlemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.
DB00108NatalizumabFor treatment of multiple sclerosis.
DB00111DaclizumabZenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection
DB01257EculizumabFor the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
DB01270RanibizumabFor the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
DB04949PexelizumabFor the treatment of inflammation during cardiac surgery.
DB04958EpratuzumabInvestigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
DB05097LabetuzumabLabetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"
DB05101MatuzumabInvestigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.
DB05111FontolizumabInvestigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
DB05496OtelixizumabInvestigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.
DB05595FarletuzumabInvestigated for use/treatment in ovarian cancer.
DB05656VeltuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's).
DB05679UstekinumabUstekinumab is indicated for management of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; or is used alone or in conjunction with methotrexate for the management of active psoriatic arthritis in adults. The FDA approved the use of ustekinumab in September 2016 for the treatment of moderate to severe Crohn's disease. The use of ustekinumab may improve short term clinical response but not clinical remission in moderate to severe Crohn's disease.
DB05797TNX-901Investigated for use/treatment in allergic reaction.
DB05889Inotuzumab ozogamicinIndicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL).
DB05892RI 624Investigated for use/treatment in pain (acute or chronic).
DB06273TocilizumabIndicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
DB06317ElotuzumabIndicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
DB06602ReslizumabInvestigated for use/treatment in esophageal disorders and pediatric indications.
DB06612MepolizumabMepolizumab is indicated for add-on maintenance treatment of severe eosinophilic asthma, as identified by blood eosinophils greater than or equal to 150 cells/μl at initiation of treatment or blood eosinophils greater than or equal to 300 cells/μl in the past 12 months, in patients aged 12 years and older. Mepolizumab has been shown to reduce exacerbations of asthma in patients with an exacerbation history
DB06643DenosumabProlia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass. Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors.
DB08879BelimumabAdjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
DB08904Certolizumab pegolReducing signs and symptoms of Crohn's disease and treatment of moderately to severely active rheumatoid arthritis (RA).
DB09033VedolizumabVedolizumab is indicated for adult patients with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
DB09264IdarucizumabFor use in patients treated with Dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding.
DB11569Ixekizumab Ixekizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
DB11715BapineuzumabNot Available
DB11756SolanezumabNot Available
DB11767SarilumabIndicated for modere to severe reactive RA in adult patients who are irresponsive, respond inadequately or present intolerance to disease-modifying anti-rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. It is indicated to be used in combination with methotrexate (MTX) or as a monotherapy when there is intolerance to MTX or MTX administration is inappropriate.
DB11849EmibetuzumabNot Available
DB11856LigelizumabNot Available
DB11862LandogrozumabNot Available
DB11988OcrelizumabOcrelizumab is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis.
DB12023BenralizumabBenralizumab is indicated as a maintenance treatment of patients 12 years or older with severe asthma and an eosinophilic phenotype.[L1020] The pathology of severe asthma with eosinophilic phenotype is also denotated as TH2-high phenotype. The patients with this phenotype are characterized by the expression of IL-5 and IL-13, airway hyperresponsiveness, responsiveness to inhaled corticosteroids, high serum IgE and eosinophilia in blood and airway. In the TH2-high phenotype, IL-5 presents a central role as it is responsible for eosinophil differentiation, survival, activation and migration to the lungs.[A31295]
DB12053VisilizumabNot Available
DB12119GevokizumabNot Available
DB12189EtrolizumabNot Available
DB12213EtaracizumabNot Available
DB12274AducanumabNot Available
DB12335TanezumabNot Available
DB12456BococizumabNot Available
DB12489Mirvetuximab SoravtansineNot Available
DB12498MogamulizumabNot Available
DB12530InebilizumabNot Available
DB12560BlosozumabNot Available
DB12589DacetuzumabNot Available
DB12609TovetumabNot Available
DB12732FirategrastNot Available
DB12734DemcizumabNot Available
DB12775AbituzumabNot Available
DB12820ConcizumabNot Available
DB12826DepatuxizumabNot Available
DB12844RontalizumabNot Available
DB12849ClazakizumabNot Available
DB12891OzanezumabNot Available
DB12893Sacituzumab govitecanNot Available
DB12943MilatuzumabNot Available
DB13127OlokizumabNot Available
DB01269PanitumumabFor the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
DB05578RamucirumabFor use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
DB06186IpilimumabIpilimumab is indicated for the treatment of unresectable or metastatic melanoma in adults. It is also used to reduce the risk of the deadly skin cancer returning after surgery.
DB06650OfatumumabOfatumumab is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
DB08870Brentuximab vedotinUsed in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
DB09035NivolumabNivolumab is indicated for the treatment of unresectable or metastatic melanoma for patients who no longer respond to treatment with other drugs. It is intended for use in patients who have been previously treated with ipilimumab and is used for melanoma patients after treatment with ipilimumab and a BRAF inhibitor in patients whose tumors express BRAF V600 gene mutations. Historically there have been very few effective treatments for advanced melanoma, which is why this product was approved under an FDA accelerated program to allow earlier patient access.
DB09052BlinatumomabIndicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
DB09077DinutuximabDinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.
DB09559NecitumumabNecitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC.
DrugDrug NameTargetType
DB00002CetuximabEpidermal growth factor receptortarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00002CetuximabComplement C1r subcomponenttarget
DB00002CetuximabComplement C1q subcomponent subunit Atarget
DB00002CetuximabComplement C1q subcomponent subunit Btarget
DB00002CetuximabComplement C1q subcomponent subunit Ctarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00002CetuximabComplement C1s subcomponenttarget
DB00002CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00072TrastuzumabComplement C1r subcomponenttarget
DB00072TrastuzumabComplement C1q subcomponent subunit Atarget
DB00072TrastuzumabComplement C1q subcomponent subunit Btarget
DB00072TrastuzumabComplement C1q subcomponent subunit Ctarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00072TrastuzumabComplement C1s subcomponenttarget
DB00072TrastuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00072TrastuzumabReceptor tyrosine-protein kinase erbB-2target
DB00072TrastuzumabEpidermal growth factor receptortarget
DB00072TrastuzumabCytochrome P450 19A1enzyme
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00073RituximabComplement C1r subcomponenttarget
DB00073RituximabComplement C1q subcomponent subunit Atarget
DB00073RituximabComplement C1q subcomponent subunit Btarget
DB00073RituximabComplement C1q subcomponent subunit Ctarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00073RituximabComplement C1s subcomponenttarget
DB00073RituximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00073RituximabB-lymphocyte antigen CD20target
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00112BevacizumabComplement C1r subcomponenttarget
DB00112BevacizumabComplement C1q subcomponent subunit Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Btarget
DB00112BevacizumabComplement C1q subcomponent subunit Ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00112BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabVascular endothelial growth factor Atarget
DB05773Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
DB05773Trastuzumab emtansineMultidrug resistance protein 1transporter
DB05773Trastuzumab emtansineCytochrome P450 3A4enzyme
DB05773Trastuzumab emtansineCytochrome P450 3A5enzyme
DB06366PertuzumabReceptor tyrosine-protein kinase erbB-2target
DB08935ObinutuzumabB-lymphocyte antigen CD20target
DB09037PembrolizumabProgrammed cell death protein 1target
DB00056Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00056Gemtuzumab ozogamicinComplement C1r subcomponenttarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Atarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Btarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Ctarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00056Gemtuzumab ozogamicinComplement C1s subcomponenttarget
DB00056Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00110PalivizumabFusion glycoprotein F0target
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00110PalivizumabComplement C1r subcomponenttarget
DB00110PalivizumabComplement C1q subcomponent subunit Atarget
DB00110PalivizumabComplement C1q subcomponent subunit Btarget
DB00110PalivizumabComplement C1q subcomponent subunit Ctarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00110PalivizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit alphatarget
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit betatarget
DB00051AdalimumabTumor necrosis factortarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00051AdalimumabComplement C1r subcomponenttarget
DB00051AdalimumabComplement C1q subcomponent subunit Atarget
DB00051AdalimumabComplement C1q subcomponent subunit Btarget
DB00051AdalimumabComplement C1q subcomponent subunit Ctarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00051AdalimumabComplement C1s subcomponenttarget
DB00051AdalimumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00065InfliximabTumor necrosis factortarget
DB00075MuromonabT-cell surface glycoprotein CD3 epsilon chaintarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00075MuromonabComplement C1r subcomponenttarget
DB00075MuromonabComplement C1q subcomponent subunit Atarget
DB00075MuromonabComplement C1q subcomponent subunit Btarget
DB00075MuromonabComplement C1q subcomponent subunit Ctarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00075MuromonabComplement C1s subcomponenttarget
DB00075MuromonabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00075MuromonabT-cell surface glycoprotein CD3 delta chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 gamma chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 zeta chaintarget
DB00087AlemtuzumabCAMPATH-1 antigentarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00087AlemtuzumabComplement C1r subcomponenttarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Atarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Btarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Ctarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00087AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00108NatalizumabIntegrin alpha-4target
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00108NatalizumabComplement C1r subcomponenttarget
DB00108NatalizumabComplement C1q subcomponent subunit Atarget
DB00108NatalizumabComplement C1q subcomponent subunit Btarget
DB00108NatalizumabComplement C1q subcomponent subunit Ctarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00108NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00108NatalizumabIntercellular adhesion molecule 1target
DB00111DaclizumabInterleukin-2 receptor subunit alphatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00111DaclizumabComplement C1r subcomponenttarget
DB00111DaclizumabComplement C1q subcomponent subunit Atarget
DB00111DaclizumabComplement C1q subcomponent subunit Btarget
DB00111DaclizumabComplement C1q subcomponent subunit Ctarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00111DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00111DaclizumabInterleukin-2 receptor subunit betatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB01257EculizumabComplement C5target
DB01270RanibizumabVascular endothelial growth factor Atarget
DB04958EpratuzumabB-cell receptor CD22target
DB05097LabetuzumabCarcinoembryonic antigentarget
DB05101MatuzumabEpidermal growth factor receptortarget
DB05111FontolizumabInterferon gammatarget
DB05595FarletuzumabFolate receptor alphatarget
DB05679UstekinumabInterleukin-12 subunit betatarget
DB05679UstekinumabInterleukin-23target
DB05797TNX-901High affinity immunoglobulin epsilon receptor subunit alphatarget
DB05889Inotuzumab ozogamicinMultidrug resistance protein 1transporter
DB05889Inotuzumab ozogamicinB-cell receptor CD22target
DB05892RI 624Beta-nerve growth factortarget
DB06273TocilizumabInterleukin-6 receptor subunit alphatarget
DB06317ElotuzumabSLAM family member 7target
DB06612MepolizumabInterleukin-5target
DB06643DenosumabTumor necrosis factor ligand superfamily member 11target
DB08879BelimumabTumor necrosis factor ligand superfamily member 13Btarget
DB08904Certolizumab pegolTumor necrosis factortarget
DB09033VedolizumabIntegrin alpha-4target
DB09033VedolizumabIntegrin beta-7target
DB09264IdarucizumabDabigatran etexilatetarget
DB11569IxekizumabInterleukin-17Atarget
DB11767SarilumabAlanine aminotransferase 1enzyme
DB11767SarilumabAlanine aminotransferase 2enzyme
DB11767SarilumabAspartate aminotransferaseenzyme
DB11767SarilumabCytochrome P450 3A4enzyme
DB11767SarilumabInterleukin-6 receptor subunit alphatarget
DB11767SarilumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB11988OcrelizumabB-lymphocyte antigen CD20target
DB12023BenralizumabInterleukin-5 receptor subunit alphatarget
DB12023BenralizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB12119GevokizumabInterleukin-1 betatarget
DB01269PanitumumabEpidermal growth factor receptortarget
DB05578RamucirumabVascular endothelial growth factor receptor 2target
DB06186IpilimumabCytotoxic T-lymphocyte protein 4target
DB06650OfatumumabB-lymphocyte antigen CD20target
DB08870Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
DB08870Brentuximab vedotinCytochrome P450 3A4enzyme
DB08870Brentuximab vedotinCytochrome P450 3A5enzyme
DB08870Brentuximab vedotinMultidrug resistance protein 1transporter
DB09035NivolumabProgrammed cell death protein 1target
DB09052BlinatumomabB-lymphocyte antigen CD19target
DB09052BlinatumomabT-cell surface glycoprotein CD3 delta chaintarget
DB09077DinutuximabGanglioside GD2target
DB09559NecitumumabEpidermal growth factor receptortarget